32 results about "Breast tissue sample" patented technology

Methods and compositions are provided for the identification of expression signatures in ER+ breast cancer cases, where the signatures correlate with responsiveness, or lack thereof, to tamoxifen treatment. The signature profiles are identified based upon sampling of reference breast tissue samples from independent cases of breast cancer and provide a reliable set of molecular criteria for predicting the efficacy of treating a subject with ER+ breast cancer with tamoxifen. Additional methods and compositions are provided for predicting tamoxifen responsiveness in cases of ER+ breast cancer by use of three biomarkers. Two biomarkers display increased expression correlated with tamoxifen response while the third biomarker displays decreased expression correlated with tamoxifen response.

Methods and compositions for the identification of breast cancer grade signatures are provided. The signature profiles are identified based upon multiple sampling of reference breast tissue samples from independent cases of breast cancer and provide a reliable set of molecular criteria for identification of cells as being in one or more particular stages and/or grades of breast cancer.

Methods and compositions for the identification of breast cancer progression signatures are provided. The signature profiles are identified based upon multiple sampling of reference breast tissue samples from independent cases of breast cancer and provide a reliable set of molecular criteria for identification of cells as being in one or more particular stages of breast cancer.

Methods and compositions are provided for the identification of expression signatures in ER+ breast cancer cases, where the signatures correlate with responsiveness, or lack thereof, to treatment with tamoxifen or another antiestrogen agent against breast cancer The signature profiles are identified based upon sampling of reference breast tissue samples from independent cases of breast cancer and provide a reliable set of molecular criteria for predicting the efficacy of treating a subject with breast cancer with tamoxifen or another antiestrogen agent against breast cancer. Additional methods and compositions are provided for predicting responsiveness to tamoxifen or another antiestrogen agent against breast cancer in cases of breast cancer by use of three biomarkers. Two biomarkers display increased expression correlated with tamoxifen response while the third biomarker displays decreased expression correlated with tamoxifen response.

Methods, systems, and apparatuses for automatically identifying glandular regions and tubule regions in a breast tissue sample are provided. An image of breast tissue is analyzed to detect nuclei and lumen candidates, identify tumor nuclei and true lumen from the candidates, and group tumor nuclei with neighboring tumor nuclei and lumina to define tubule glandular regions and non-tubule glandular regions of the image. Learnt supervised classifiers, such as random forest classifiers, can be applied to identify and classify the tumor nuclei and true lumina. Graph-cut methods can be applied to group the tumor nuclei and lumina and to define the tubule glandular regions and non-tubule glandular regions. The analysis can be applied to whole slide images and can resolve tubule areas with multiple layers of nuclei.

Methods and compositions are provided for the identification of expression signatures in ER+ breast cancer cases, where the signatures correlate with responsiveness, or lack thereof, to treatment with tamoxifen or another antiestrogen agent against breast cancer The signature profiles are identified based upon sampling of reference breast tissue samples from independent cases of breast cancer and provide a reliable set of molecular criteria for predicting the efficacy of treating a subject with breast cancer with tamoxifen or another antiestrogen agent against breast cancer. Additional methods and compositions are provided for predicting responsiveness to tamoxifen or another antiestrogen agent against breast cancer in cases of breast cancer by use of multiple biomarkers. Two biomarkers display increased expression correlated with tamoxifen response while two other biomarkers display decreased expression correlated with tamoxifen response.

The present invention relates to methods of determining the predilection for survival for an individual having breast cancer comprising: obtaining a breast tissue sample from said individual, measuring the amount of Wrap53 in the nucleus of cells in said breast tissue sample, and/or measuring the amount of Wrap53 in the cytoplasm of cells in said breast tissue sample, and wherein both the nuclear levels, the cytoplasmic levels and/or the ratio between the nuclear and cytoplasmic levels of Wrap53 may be used alone or in combination in breast cancer prognosis. The invention furthermore relates to antibodies and kits relating to Wrap53.

The present invention includes methods for identifying patients who will be resistant to endocrine therapy during breast cancer treatment and determining patient outcome. The methods are based on identifying increased expression of PBX1, or the cistrome signature associated therewith, in breast tissue samples.

Methods of identifying a mammal having an increased likelihood of recurrence of breast cancer includes identifying in a breast tissue sample of the mammal expression of at least two genes selected from the group consisting of Hs.125867 (EVL), Hs.591847 (NAT1), Hs.208124 (ESR1), Hs.26225 (GABRP), Hs.408614 (ST8SIA1), Hs.480819 (TBC1D9), Hs.504115 (TRIM29), Hs.523468 (SCUBE2), Hs.532082 (IL6ST), Hs.592121 (RABEP1), Hs.79136 (SLC39A6), Hs.82128 (TPBG), Hs.95243 (TCEAL1), Hs.95612 (DSC2), Hs.654961 (FUT8), Hs.1594 (CENPA), Hs.184339 (MELK), Hs.26010 (PFKP), Hs.592049 (PLK1), Hs.370834 (ATAD2), Hs.437638 (XBP1), Hs.444118 (MCM6), Hs.469649 (BUB1), Hs.470477 (PTP4A2), Hs.473583 (YBX1), Hs.480938 (LRBA), Hs.524134 (GATA3), Hs.531668 (CX3CL1), Hs.532824 (MAPRE2), Hs.591314 (GMPS), Hs.83758 (CKS2) and Hs.99962 (SLC43A3) and subsets of the genes.

The present invention describes methods for determining the risk that a breast precursor lesion will progress to invasive breast cancer and/or the risk of recurrent non-invasive disease in a patient, comprising detecting the presence and/or level of PAPPA and/or PAPPA functional activity in a breast tissue sample obtained from the patient, wherein if PAPPA is not present, or is present at a reduced amount compared to a control, there is the risk of progression to invasive cancer and/or the risk or recurrent disease.

The present invention also enables the chemosensitisation of mitotically delayed breast cancer cells to anti-proliferative agents, preferably anti-mitotic agents, by restoring normal progression through mitosis. In this embodiment a first drug is applied to release breast cancer cells from the mitotic block and, sequentially, a second drug affecting proliferating cells is administered for cancer cell killing.

The present invention relates to the field of breast cancer diagnosis and treatment. The present invention provides methods comprising a) analysing a biological sample obtained from a subject to determine the presence of target molecules representative of expression of at least two biomarkers selected from the group listed in Table 1, wherein the biological sample is a breast tissue sample or derivative thereof; and b) comparing the expression levels of the biomarkers determined in (a) with one or more reference values, wherein whether there is a difference in the expression of the biomarkers in the sample from the subject compared to the one or more reference values is indicative of a clinical indication. The invention further provides methods of treatment and kits and assays for use in the methods of the invention.

The invention discloses a high spectral imaging system for breast preset electrical level-raised square wave frequency coding. The high spectral imaging system includes driving all the single-color light sources by using preset electrical level-raised square waves with different frequencies, wherein each pixel point of an image received by a camera is a combination of single-color light of each single-color light source penetrating a breast tissue sample. When the camera acquires the image, the noise level does not change, a square signal as a drive is raised in a preset electrical level, the square signal is more obvious in improvement than noise in a low electrical level part of the square signal, the signal to noise ratio of the image acquired by the camera is improved in a low electrical level segment of the square signal, and then the precision of the combination of the single-color light input in a computer can be improved; and the computer can separate the combination of the single-color light so as to acquire a contribution of each single-color light source in the combination of the single-color light, and accordingly, imaging of transmission high spectrogram of the breast tissue sample can be achieved.

Disclosed are methods of predicting the likelihood of long-term survival without recurrence of breast cancer for a subject having estrogen receptor-positive (ER+) breast cancer treated with adjuvant endocrine monotherapy. In various embodiments, these methods comprise performing a gene expression profile of a breast tissue sample of substantially all of the genes of the “CADER set” described herein; calculating a risk score using a regression model; and applying a double median cutoff classification to assign the subject to a sensitive, indeterminate or resistant group, wherein assignment to a sensitive group predicts longer relapse-free survival compared to the median relapse-free survival of ER+ breast cancer patients treated with adjuvant endocrine monotherapy.